Mylan N.V. (MYL) : 6 Wall Street analysts covering Mylan N.V. (MYL) believe that the average level the stock could reach for the short term is $58.5. The maximum price target given is $66 and the minimum target for short term is around $52, hence the standard deviation is calculated at $6.02.
Mylan N.V. (MYL) : 3 brokerage houses believe that Mylan N.V. (MYL) is a Strong Buy at current levels. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Mylan N.V. (MYL). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 8 Wall Street Analysts endorse the stock as a Buy with a rating of 2.25.
Also, Major Brokerage house, Leerink Swann maintains its ratings on Mylan N.V. (NASDAQ:MYL). In the latest research report, Leerink Swann raises the target price from $51 per share to $55 per share. According to the latest information available, the shares are now rated Outperform by the analysts at the agency. The rating by the firm was issued on August 15, 2016.
Mylan N.V. (NASDAQ:MYL): The stock opened at $42.52 on Thursday but the bulls could not build on the opening and the stock topped out at $42.63 for the day. The stock traded down to $41.55 during the day, due to lack of any buying support eventually closed down at $41.92 with a loss of -1.04% for the day. The stock had closed at $42.36 on the previous day. The total traded volume was 5,691,722 shares.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.